Distinguished in WT1-Related Wilms Tumor Syndromes

Dr. Christos Kyriakopoulos

Hematology
University Hospital
600 Highland Ave, 
Madison, WI 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Distinguished in WT1-Related Wilms Tumor Syndromes
University Hospital
600 Highland Ave, 
Madison, WI 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Christos Kyriakopoulos is a Hematologist in Madison, Wisconsin. Dr. Kyriakopoulos is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Prostate Cancer, Renal Cell Carcinoma (RCC), Clear Cell Sarcoma, WT1-Related Wilms Tumor Syndromes, and Nephrectomy.

His clinical research consists of co-authoring 53 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Licenses
Internal Medicine in WI
Hospital Affiliations
University Of Wi Hospitals & Clinics Authority
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Aspirus Arise Health
  • HMO
  • POS
Cigna
  • EPO
  • HMO
  • PPO
Dean Health
  • EPO
  • HMO
  • POS
  • PPO
Group Health Cooperative
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MercyCare
  • EPO
  • HMO
Quartz
  • HMO
  • POS
  • PPO
Quartz Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Security Health
  • EPO
  • HMO
  • INDEMNITY
  • POS
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

University Hospital
600 Highland Ave, Madison, WI 53792
Other Locations
University of Wisconsin Hospitals and Clinics Authority
4621 Eastpark Blvd, Madison, WI 53718

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer
A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer
Enrollment Status: Recruiting
Publish Date: April 15, 2025
Intervention Type: Drug
Study Drugs: Sacituzumab govitecan, Sacituzumab govitecan+Pembrolizumab, IMMU-132+Cisplatin, IMMU-132+Cisplatin+Avelumab
Study Phase: Phase 2
A Phase 1/2 Study of Combination Olaparib and Radium-223 in Men With Metastatic Castration-Resistant Prostate Cancer With Bone Metastases (COMRADE)
A Phase 1/2 Study of Combination Olaparib and Radium-223 in Men With Metastatic Castration-Resistant Prostate Cancer With Bone Metastases (COMRADE)
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Other, Procedure, Drug, Radiation
Study Drugs: Olaparib, Radium-223
Study Phase: Phase 1/Phase 2
Cabazitaxel With Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial
Cabazitaxel With Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial
Enrollment Status: Active_not_recruiting
Publish Date: January 29, 2026
Intervention Type: Drug
Study Drugs: Abiraterone acetate, Antiandrogen therapy, Cabazitaxel, Prednisone
Study Phase: Phase 2
Phase II Trial of pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer
Phase II Trial of pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 05, 2025
Intervention Type: Biological, Drug
Study Drugs: pTVG-HP, pTVG-AR, Pembrolizumab, rhGM-CSF
Study Phase: Phase 2
A Multi-arm, Phase 2 Study to Evaluate the Safety and Efficacy of Sacituzumab Govitecan in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Progressed on Second Generation AR-Directed Therapy
A Multi-arm, Phase 2 Study to Evaluate the Safety and Efficacy of Sacituzumab Govitecan in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Progressed on Second Generation AR-Directed Therapy
Enrollment Status: Active_not_recruiting
Publish Date: May 13, 2025
Intervention Type: Drug
Study Drug: IMMU-132
Study Phase: Phase 2
Neoadjuvant Gemcitabine, Cisplatin, Plus Nivolumab in Patients With Muscle-invasive Bladder Cancer With Selective Bladder Sparing
Neoadjuvant Gemcitabine, Cisplatin, Plus Nivolumab in Patients With Muscle-invasive Bladder Cancer With Selective Bladder Sparing
Enrollment Status: Completed
Publish Date: June 27, 2024
Intervention Type: Drug
Study Drugs: Nivolumab, Gemcitabine, Cisplatin
Study Phase: Phase 2
Pilot Neoadjuvant Trial of Chemohormonal Therapy Followed by Prostatectomy in Patients With High Risk or Oligometastatic Prostate Cancer
Pilot Neoadjuvant Trial of Chemohormonal Therapy Followed by Prostatectomy in Patients With High Risk or Oligometastatic Prostate Cancer
Enrollment Status: Completed
Publish Date: May 03, 2024
Intervention Type: Drug, Radiation
Study Drugs: Docetaxel, Degarelix, Bicalutamide
Study Phase: Early Phase 1
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients With Selected Solid Tumors
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients With Selected Solid Tumors
Enrollment Status: Completed
Publish Date: April 19, 2022
Intervention Type: Drug, Biological
Study Drugs: GEN-009 Adjuvant Vaccine, Nivolumab, Pembrolizumab
Study Phase: Phase 1/Phase 2
A Phase I Study of a DNA Vaccine Encoding Androgen Receptor Ligand-Binding Domain (AR LBD), With or Without Granulocyte Macrophage Colony-Stimulating Factor Adjuvant, in Patients With Metastatic Prostate Cancer
A Phase I Study of a DNA Vaccine Encoding Androgen Receptor Ligand-Binding Domain (AR LBD), With or Without Granulocyte Macrophage Colony-Stimulating Factor Adjuvant, in Patients With Metastatic Prostate Cancer
Enrollment Status: Completed
Publish Date: February 04, 2021
Intervention Type: Biological
Study Phase: Phase 1
A Phase I Study of PCUR-101 in Combination With Androgen Suppression Therapy in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer
A Phase I Study of PCUR-101 in Combination With Androgen Suppression Therapy in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer
Enrollment Status: Terminated
Publish Date: March 09, 2020
Intervention Type: Drug
Study Phase: Phase 1
A Phase 2 Open-label Study to Evaluate the Efficacy and Safety of Seviteronel in Subjects With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone
A Phase 2 Open-label Study to Evaluate the Efficacy and Safety of Seviteronel in Subjects With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone
Enrollment Status: Completed
Publish Date: February 01, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 10 Less Clinical Trials

53 Total Publications

Quantifying partial pathological response rate in prostate cancer patients who underwent neoadjuvant chemotherapy using a novel morphometric approach.
Quantifying partial pathological response rate in prostate cancer patients who underwent neoadjuvant chemotherapy using a novel morphometric approach.
Journal: Journal of pathology informatics
Published: September 02, 2025
Similar Doctors
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Hamid Emamekhoo
Hematology Oncology | Hematology | Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Hamid Emamekhoo
Hematology Oncology | Hematology | Oncology

University Of Wisconsin Medical Foundation Inc

1040 Division St, 
Mauston, WI 
 (81.9 miles away)
608-847-7355
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Hamid Emamekhoo is a Hematologist Oncology specialist and a Hematologist in Mauston, Wisconsin. Dr. Emamekhoo is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Renal Cell Carcinoma (RCC), Prostate Cancer, Urothelial Cancer, Nephrectomy, and Tissue Biopsy. Dr. Emamekhoo is currently accepting new patients.

Joanna Zurko
Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Joanna Zurko
Hematology | Oncology
Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Joanna Zurko
Hematology | Oncology

SSM Health Cancer Care

1211 Fish Hatchery Road, 
Madison, WI 
 (32.2 miles away)
608-410-2700
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Joanna Zurko is a Hematologist and an Oncologist in Madison, Wisconsin. Dr. Zurko is rated as an Advanced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. Her top areas of expertise are Multiple Myeloma, Clear Cell Sarcoma, Chromophobe Renal Cell Carcinoma, and WT1-Related Wilms Tumor Syndromes.

Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Christopher Hake
Hematology | Oncology
Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Christopher Hake
Hematology | Oncology

UW Health Cancer Center At ProHealth Care Pewaukee

N16W24131 Riverwood Dr, 
Waukesha, WI 
 (27.2 miles away)
262-696-5690
Languages Spoken:
English
See accepted insurances

Christopher Hake is a Hematologist and an Oncologist in Waukesha, Wisconsin. Dr. Hake is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Angiosarcoma, Inflammatory Breast Cancer, Paget Disease of the Breast, and Breast Cancer.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kyriakopoulos's expertise for a condition
ConditionClose
View All 8 Distinguished Conditions
View All 29 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile